Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China
· Delayed Price · Currency is CNY 29.90
-1.44 (-4.59%)
Last updated: Jun 6, 2025
SHA:688443 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -754.23 | -797.27 | -801.32 | -576.37 | -322.13 | -372.62 | Upgrade
|
| Depreciation & Amortization | 66.65 | 66.65 | 59.17 | 49.94 | 38.5 | 31.28 | Upgrade
|
| Other Amortization | 7.94 | 7.94 | 4.61 | 3.69 | 5.56 | 3.21 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | 0 | - | -0 | - | -0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.54 | 0.54 | 0 | 0 | 0.7 | 1.82 | Upgrade
|
| Loss (Gain) From Sale of Investments | -2.73 | -2.73 | -1.94 | -7.86 | -4.13 | -0.64 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.63 | 0.63 | - | - | -0.03 | 0.03 | Upgrade
|
| Other Operating Activities | 20.34 | 29.51 | 34.01 | 33.99 | 32.15 | 34.41 | Upgrade
|
| Change in Accounts Receivable | -40.88 | -40.88 | 9.88 | -7.71 | -105.1 | 150.15 | Upgrade
|
| Change in Inventory | 4.69 | 4.69 | 1.85 | -22.67 | -17.81 | -4.66 | Upgrade
|
| Change in Accounts Payable | 1.73 | 1.73 | 51.1 | 55.87 | 131.8 | -124.26 | Upgrade
|
| Change in Other Net Operating Assets | 153.76 | 153.76 | 265.07 | 293.47 | 2.68 | 140.89 | Upgrade
|
| Operating Cash Flow | -541.56 | -575.44 | -377.58 | -177.64 | -237.82 | -140.39 | Upgrade
|
| Capital Expenditures | -53.36 | -45.32 | -90.98 | -146.21 | -112.7 | -56.4 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.04 | 0.04 | - | - | 0 | - | Upgrade
|
| Investment in Securities | -701.01 | -382.28 | 211.6 | 194.2 | -409.24 | -0.35 | Upgrade
|
| Other Investing Activities | 2.01 | 0.14 | - | 3.4 | 1.12 | 0.44 | Upgrade
|
| Investing Cash Flow | -752.32 | -427.42 | 120.62 | 51.4 | -520.82 | -56.31 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 73.32 | 219.7 | Upgrade
|
| Long-Term Debt Issued | - | 212.91 | 109.63 | 208.35 | 186.79 | 101.25 | Upgrade
|
| Total Debt Issued | 298.01 | 212.91 | 109.63 | 208.35 | 260.11 | 320.95 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -499.15 | -180.05 | Upgrade
|
| Long-Term Debt Repaid | - | -23.39 | -257.25 | -14.88 | -9.07 | -1.03 | Upgrade
|
| Total Debt Repaid | -23.39 | -23.39 | -257.25 | -14.88 | -508.22 | -181.08 | Upgrade
|
| Net Debt Issued (Repaid) | 274.62 | 189.52 | -147.62 | 193.48 | -248.11 | 139.87 | Upgrade
|
| Issuance of Common Stock | - | - | 3,308 | - | 1,000 | 150 | Upgrade
|
| Repurchase of Common Stock | -14.68 | -14.68 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -29.05 | -28.67 | -35.02 | -32.1 | -21.59 | -14.22 | Upgrade
|
| Other Financing Activities | -3.98 | - | -25.41 | - | - | -44.77 | Upgrade
|
| Financing Cash Flow | 226.92 | 146.17 | 3,100 | 161.37 | 730.3 | 230.88 | Upgrade
|
| Net Cash Flow | -1,067 | -856.69 | 2,843 | 35.13 | -28.34 | 34.17 | Upgrade
|
| Free Cash Flow | -594.92 | -620.75 | -468.56 | -323.85 | -350.52 | -196.8 | Upgrade
|
| Free Cash Flow Margin | -1184.06% | -2062.65% | -38675.98% | -68143.75% | -894.41% | -18092.66% | Upgrade
|
| Free Cash Flow Per Share | -1.62 | -1.69 | -1.46 | -1.18 | -1.27 | - | Upgrade
|
| Cash Income Tax Paid | 6.03 | 4 | -21.69 | -57.48 | -17.5 | -15.67 | Upgrade
|
| Levered Free Cash Flow | -370.48 | -413.65 | -267.97 | -190.87 | -715.31 | -87.28 | Upgrade
|
| Unlevered Free Cash Flow | -352.25 | -395.59 | -246.1 | -170.4 | -695.05 | -65.77 | Upgrade
|
| Change in Net Working Capital | 16.79 | 52.36 | -13.1 | -10.41 | 437.83 | -37.12 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.